Lindis Blood Care GmbH | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Lindis Blood Care GmbH

Home
Companies
Lindis Blood Care GmbH

BRIEF

published on 09/15/2025 at 10:05, 2 months 19 days ago

Final Results of REMOVE Study with CATUVAB® Published

REMOVE Study Results CATUVAB® Device Oncology Blood Salvage Transfusion Safety Antibody-Based Cell Removal
PRESS RELEASE

published on 09/15/2025 at 10:00, 2 months 19 days ago

Lindis Blood Care Announces Publication of Final Results from Pivotal REMOVE Study with CATUVAB® in the Journal of Clinical Anesthesia
Lindis Blood Care announces successful results of the pivotal REMOVE study with CATUVAB® in cancer surgery, demonstrating safety and efficacy in removing EpCAM-positive tumor cells from salvaged blood

Lindis Blood Care REMOVE Study Cancer Surgery CATUVAB Transfusion Safety
BRIEF

published on 12/12/2024 at 10:05, 11 months 23 days ago

Lindis Blood Care Secures Funding for CATUVAB® Development

Medical Device Clinical Study Funding Round Cancer Surgery Market Launch
PRESS RELEASE

published on 12/12/2024 at 10:00, 11 months 23 days ago

Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®
Lindis Blood Care secures financing for CATUVAB(R) tumor-cell-removal device, aiming at cancer surgery safety and efficacy enhancements

Financing Medical Device Lindis Blood Care CATUVAB Tumor-cell-removal
BRIEF

published on 04/22/2024 at 14:05, 1 year 7 months ago

Lindis Blood Care Announces Success in REMOVE Clinical Study with CATUVAB® for Cancer Surgeries

CATUVAB® Cancer Surgery REMOVE Clinical Study Autologous Blood Transfusion Market Authorization
PRESS RELEASE

published on 04/22/2024 at 14:00, 1 year 7 months ago

Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries
Lindis Blood Care announces positive results from the REMOVE study showcasing the effectiveness of CATUVAB(R) in enabling autologous blood transfusions during cancer surgeries

Lindis Blood Care REMOVE Study CATUVAB Autologous Blood Transfusions Cancer Surgeries
BRIEF

published on 04/11/2024 at 14:05, 1 year 7 months ago

Lindis Blood Care to Unveil REMOVE Study Results on CATUVAB® at NATA24 Symposium

Lindis Blood Care CATUVAB® REMOVE Study NATA24 Symposium Cancer Surgery
PRESS RELEASE

published on 04/11/2024 at 14:00, 1 year 7 months ago

Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium
Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB at NATA24 Annual Symposium in Bologna, Italy. Prof. Dr. med. Patrick Meybohm to present safety and efficacy data

Lindis Blood Care CATUVAB NATA24 Annual Symposium Clinical Certification Study Tumor Cells

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 38 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 43 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 13 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 8 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 13 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 42 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 22 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 47 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 58 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 2 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 13 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 28 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 28 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 12 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE